Annie Song supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.
She applies her background in data analytics and public health to a broad range of topics.
Before joining Avalere, Annie was a research intern with the Center for Disease Dynamics, Economics, and Policy, where she analyzed and visualized geographic data on antibiotic resistance. Additionally, Annie interned with the Trenton Health Team, where she supported local health policy initiatives.
Annie has an AB in ecology and evolutionary biology from Princeton University.
Authored Content
Use of the three-day waiver was stable over the course of the pandemic, though shifts in admission sources were observed.
An Avalere analysis assessing differences in Medicare expenditures and utilization across 4 models provides a new perspective on the evolving physician affiliation model landscape.
If CMS lowers the dual-eligible enrollment threshold it uses to define D-SNP look-alikes, the demographics in look-alike plan enrollment will likely change.
In recent years, Medicare Part D plan tier placement of generic prescription drugs has declined, from 64.5% in 2016 to 43.8% in 2024.
Due to increasing the portion of plan payments subject to risk adjustments in 2025, CMS proposed aligning the risk adjustment model with Part D redesign.
Use of the 3-day waiver was stable over the course of the pandemic, though shifts in admission sources were observed.
Updated Avalere analysis finds MA beneficiaries with chronic conditions had fewer inpatient stays and ED visits than FFS Medicare beneficiaries.
Data analysis finds that 53% of the API, in dollars, used in domestically consumed medicines came from the US in 2021, and 85% came from the US or Europe.
Due to changes proposed in the CY 2024 Advance Notice, enrollees in Medicare Advantage could have higher premiums and fewer benefits in 2024 than 2023.
Proposed technical changes to the MA risk adjustment model would have major implications if finalized.
Analysis shows adding prescription drug copay caps to Part D benefit redesign could reduce OOP costs by 45% per enrollee.
Changes in clinical and social risk among Medicare beneficiaries treated in SNFs at the start of the pandemic reflect challenges facing the healthcare sector during a public health emergency.
Avalere estimates that the CMMI will produce net costs of approximately $9.4 billion through 2026, in contrast to the CBO’s projected net savings of $34 billion.
As climate change continues to alter the patterns of everyday life, healthcare stakeholders should consider strategies to prevent and mitigate negative environmental contributions and proactively address the impacts of climate change on health outcomes, health equity, and healthcare costs.
Analysis of the most recent available trade data finds that 53% of API, in dollars, used in domestically consumed medicines came from the US in 2020.
Worse air quality leads to preventable negative health outcomes that increase healthcare costs. Further, urban and minority populations are often exposed to disproportionate pollution risks, leading to impaired health and increased financial burden on both individuals and broader health and social systems.
New analysis of trade data finds that 54% of API, in dollars, used in domestically consumed medicines came from the US in 2019.